Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer

国际肿瘤学杂志 Pub Date : 2019-08-08 DOI:10.3760/CMA.J.ISSN.1673-422X.2019.08.012

Xi-Zhuang Bai, Jinmeng Zhang, Yang Sun, Yongheng An

{"title":"Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer","authors":"Xi-Zhuang Bai, Jinmeng Zhang, Yang Sun, Yongheng An","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.012","DOIUrl":null,"url":null,"abstract":"In recent years, immunotherapy has become an important part of the treatment for advanced non-small cell lung cancer (NSCLC). Tumor cells can escape from the body′s immune system by mediating various immune escape mechanisms, among which programmed death-1/programmed death ligand-1 (PD-1/PD-L1) mediated immune escape plays an important role. Currently, chemotherapy, radiotherapy and molecular targeted therapy have certain limitations in the treatment of advanced NSCLC. Recent studies have found that the combined application of PD-1/PD-L1 inhibitor and other treatment methods has certain synergistic effect, thus enhances the anti-tumor effect and further prolongs the survival of patients. Immunotherapy brings not only changes in the treatment patterns of NSCLC, but also challenges in the screening of target population and the management of treatment-related adverse reactions. Summarizing the research progress on immune checkpoint inhibitors in the comprehensive treatment of advanced NSCLC can provide reference for the best treatment of NSCLC. \n \nKey words: \nLung neoplasms; Immunotherapy; PD-1/PD-L1; Comprehensive therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"74 1","pages":"500-504"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, immunotherapy has become an important part of the treatment for advanced non-small cell lung cancer (NSCLC). Tumor cells can escape from the body′s immune system by mediating various immune escape mechanisms, among which programmed death-1/programmed death ligand-1 (PD-1/PD-L1) mediated immune escape plays an important role. Currently, chemotherapy, radiotherapy and molecular targeted therapy have certain limitations in the treatment of advanced NSCLC. Recent studies have found that the combined application of PD-1/PD-L1 inhibitor and other treatment methods has certain synergistic effect, thus enhances the anti-tumor effect and further prolongs the survival of patients. Immunotherapy brings not only changes in the treatment patterns of NSCLC, but also challenges in the screening of target population and the management of treatment-related adverse reactions. Summarizing the research progress on immune checkpoint inhibitors in the comprehensive treatment of advanced NSCLC can provide reference for the best treatment of NSCLC. Key words: Lung neoplasms; Immunotherapy; PD-1/PD-L1; Comprehensive therapy

查看原文本刊更多论文

免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用

近年来，免疫治疗已成为晚期非小细胞肺癌(NSCLC)治疗的重要组成部分。肿瘤细胞可以通过多种免疫逃逸机制逃离机体免疫系统，其中程序性死亡-1/程序性死亡配体-1 (PD-1/PD-L1)介导的免疫逃逸起着重要作用。目前，化疗、放疗和分子靶向治疗在晚期NSCLC的治疗中存在一定的局限性。近期研究发现，PD-1/PD-L1抑制剂与其他治疗方法联合应用具有一定的协同作用，从而增强抗肿瘤效果，进一步延长患者生存期。免疫治疗不仅给非小细胞肺癌的治疗模式带来了改变，也给靶人群的筛选和治疗相关不良反应的处理带来了挑战。总结免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的研究进展，可为非小细胞肺癌的最佳治疗提供参考。关键词:肺肿瘤;免疫治疗;PD-1 / PD-L1;全面的治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

国际肿瘤学杂志

自引率

0.00%

发文量

12123

期刊介绍：